Aug 8 (Reuters) -

Heartflow shares surged 47.4% in their Nasdaq

debut on Friday, giving the medtech firm a valuation of $2.27

billion, as the IPO market gathers momentum and outrides tariff

worries.

The stock opened at $28, compared with the IPO price of $19,

signaling robust investor appetite for revenue-positive

companies leveraging artificial intelligence for healthcare.

Heartflow sold about 16.67 million shares in its IPO on

Thursday and raised $316.7 million. Its raised marketed price

was $17 to $18 per share.

The Bain Capital-backed company's solid market debut comes

as expectations of a softer trade policy and lower interest

rates boost investor sentiment, which had nosedived after U.S.

tariffs in April stoked recession fears.

Space tech startup Firefly Aerospace ( FLY ) and design

software firm Figma ( FIG ) saw stellar first-day reactions in

recent days, strengthening prospects for tech-focused companies

to go public.

Heartflow's first-day pop could help boost market perception

for future medtech IPOs.

Beta Bionics ( BBNX ) and Kestra Medical ( KMTS ) had solid

debuts earlier this year, but are now trading below their IPO

price, like most medtech IPOs of the past year.